GlassScriptPhysician profile
Stephen W Johnson
NPI 1679924716
$7,860.03
in general payments reported to CMS, 2019-2025
29 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,824 · 2022: $3,260 · 2023: $1,303 · 2024: $300 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,713.06 | 2021-2025 | |
| Amgen INC. | $1,350.07 | 2021-2023 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $670.48 | 2021-2023 | Cimzia |
| Glaxosmithkline, LLC. | $518.66 | 2021-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $422.25 | 2021-2023 | Acthar |
| Janssen Biotech, INC. | $412.24 | 2021-2023 | Tremfya |
| Novartis Pharmaceuticals Corporation | $409.79 | 2021-2023 | |
| Pfizer INC. | $373.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $304.03 | 2021-2022 | |
| Horizon Therapeutics Plc | $299.85 | 2021-2022 | |
| Lilly USA, LLC | $259.40 | 2021-2023 | Taltz |
| Octapharma USA, INC. | $224.75 | 2022-2024 | Octagam Immune Globulin (Human), Cutaquig, Panzyga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.06 | 2021-2023 | |
| Surmodics, INC. | $151.26 | 2024 | Pounce Thrombectomy System, Sublime Microcatheter, 018, 200cm, Straight, Pounce Venous Thrombectomy System |
| Grt US Holding, INC. | $81.79 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $76.27 | 2021-2022 | |
| Emmaus Medical, INC. | $71.55 | 2021 | |
| Novo Nordisk INC | $63.56 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $62.67 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $42.58 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.98 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $22.21 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.95 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.40 | 2025 | Voquezna |
| Averitas Pharma INC. | $16.91 | 2023 | Qutenza |
| Seqirus USA INC | $16.28 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Fresenius Kabi USA, LLC | $15.49 | 2023 | Idacio |
| Philips North America LLC | $14.52 | 2024 | (Cm9) Amb Mon & Diag Und |
| Kaleo, INC. | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.